Alexandre Zanghellini co-founded Arzeda and leads the team as CEO and vice president of research. He is an internationally recognized protein design expert and was the early developer of Arzeda’s protein design software Archytas for enzyme design as well as Arzeda’s metabolic pathway design software Scylax. Before Arzeda, Zanghellini led bioinformatics at Cellectis (NASDAQ: CLLS), a publicly traded protein engineering and gene editing company.

He believes the convergence of big computing, machine learning, DNA synthesis and lab automation represents a turning point in human history, and that the rational design of new proteins will play a key role in solving major societal challenges — from improving human well-being to combating climate change.

Zanghellini holds a doctorate in biochemistry from the University of Washington, a master’s degree in computer science (artificial intelligence) and a bachelor’s degree in applied mathematics from the University of Paris, and a master of engineering from ENSTA/ParisTech.